20C2 [4H12:20C2.G6.C9]細(xì)胞

ATCC Number： CRL-2382?

細(xì)胞形態(tài)： **樣

**類型： IgG1

運(yùn)輸方式： 凍存運(yùn)輸

數(shù)量： 大量

生長(zhǎng)狀態(tài)： 懸浮生長(zhǎng)

是否是腫瘤細(xì)胞： 0

物種來(lái)源： 大鼠

Designations: 20C2 [4H12:20C2.G6.C9]

20C2 [4H12:20C2.G6.C9]細(xì)胞Depositors: DH Presky

Isotype: IgG1

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: suspension

Organism: Rattus norvegicus (B cell); Mus musculus (myeloma) deposited as rat (B cell); mouse (myeloma)

Morphology: lymphoblast

Source: Cell Type: hybridoma: B lymphocyte;

Cellular Products: immunoglobulin; monoclonal antibody; against human interleukin 12 (IL-12) p75

Permits/Forms: 20C2 [4H12:20C2.G6.C9]細(xì)胞In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Comments: The hybridoma cell line 20C2 [4H12:20C2.G6.C9} was established by Richard Chizzonite in 1991 and subcloned three times by limiting dilution.

The hybridoma produces an antibody (IgG1) that binds the p75 heterodimer of human IL-12.

The antibody may be used in neutralizing and receptor binding assays; it will immunoprecipitate IL-12.

The antibody can be used as a capture antibody in sandwich EIA to detect the p75 form of human IL-12.

The 20C2 antibody does not bind the p40 or p35 subunits of IL-12.

The 20C2 cell line was formed by the fusion of NSO mouse myeloma cells with splenocytes from a Lewis rat inoculated with partially purified human IL-12 p75. [38686]

Propagation: ATCC complete growth medium: Iscove's Modified Dulbecco's Medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate supplemented with 0.1 mM 2-mercaptoethanol, 90%; fetal bovine serum, 10%.

20C2 [4H12:20C2.G6.C9]細(xì)胞Temperature: 37.0°C

Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)

Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml.

Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.

Preservation: culture medium 95%; DMSO, 5%

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2020

References: 25320: Chua AO, et al. Expression cloning of a human IL-12 receptor component--a new member of the cytokine receptor superfamily with strong homology to gp130. J. Immunol. 153: 128-136, 1994. PubMed: 7911493

38686: Chizzonite R, et al. IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts. J. Immunol. 147: 1548-1556, 1991. PubMed: 1715362

38687: Chizzonite R, et al. IL-12 receptor. I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts. J. Immunol. 148: 3117-3124, 1992. PubMed: 1578138

38695: Desai BB, et al. IL-12 receptor. II. 20C2 [4H12:20C2.G6.C9]細(xì)胞Distribution and regulation of receptor expression. J. Immunol. 148: 3125-3132, 1992. PubMed: 1578139

38701: Gately MK, et alMeasurement of Human and Mouse Interleukin-12In: Gately MK, et alCurrent Protocols in ImmunologyNew York, N.Y.John Wiley and Sons1995.